Incyte Corporation
A biopharmaceutical company that develops treatments for blood cancers and other cancers (JAKAFI, ICLUSIG), plus creams for skin conditions like vitiligo and eczema (OPZELURA). Founded in 1991 in Palo Alto, it began as a genomics pioneer selling its LifeSeq gene database to researchers before pivoting to making its own drugs. Its name blends "insight" with "cyt," the Greek root for cell — a nod to its genome-sequencing roots.
Granted 84.4K
Granted 155.5K · Sold 187.5K
Granted 124.9K · Sold 56.0K
Granted 161.1K
Granted 68.6K
Granted 43.2K · Sold 8.4K
Granted 141.1K · Sold 93.5K
Granted 85.3K · Sold 10.9K
Sold 5.8K
Granted 43.2K · Sold 33.0K
Granted 41.7K · Sold 3.1K
Granted 8.1K · Sold 8.4K
Granted 47.1K · Sold 65.5K
Granted 34.0K · Sold 58.3K
Granted 60.1K · Sold 28.2K
Granted 26.3K
Granted 25.8K · Sold 15.0K
Granted 22.0K
Granted 15.0K · Sold 15.1K
Granted 10.9K
Granted 7.0K
Granted 7.0K
Granted 15.7K
Granted 7.0K
Granted 6.5K
Granted 9.5K
Granted 9.4K
Granted 5.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 34 transactions | — | 121.83M | 84.4K | — | — |
| Hoppenot HerveDirector · 11 transactions | -24.8% | 326.8K | 155.5K | — | 187.5K |
| Cagnoni Pablo JPresident, Global Head of R&D · 16 transactions | +19.2% | 240.8K | 124.9K | — | 56.0K |
| Meury WilliamChief Executive Officer, Director, President · 2 transactions | — | 161.1K | 161.1K | — | — |
| Stamoulis ChristianaEVP & Chief Financial Officer · 12 transactions | +51.5% | 125.8Kas of Jul 2025 | 68.6K | — | — |
| Swain Paula JEVP, Human Resources · 12 transactions | +23.8% | 106.5Kas of Jul 2025 | 43.2K | — | 8.4K |
| Stein Steven HCMO & Head of Late-Stage Dev. · 26 transactions | -19.7% | 78.3K | 141.1K | — | 93.5K |
| Issa Mohamed KhairieEVP, Head of US Oncology · 5 transactions | — | 66.1K | 85.3K | — | 10.9K |
| Mayes Patrick AEVP & Chief Scientific Officer · 3 transactions | — | 60.0K | — | — | 5.8K |
| Iyengar Vijay KEVP, GMAPPS · 18 transactions | -8% | 40.5Kas of Jul 2025 | 43.2K | — | 33.0K |
| Heeson LeeEVP, Head of Incyte Intl · 6 transactions | — | 38.0K | 41.7K | — | 3.1K |
| Dickinson Jonathan ElliottEVP, General Manager, Europe · 7 transactions | +0.1% | 36.4Kas of Sep 2024 | 8.1K | — | 8.4K |
| Flannelly Barry PEVP & General Manager US · 25 transactions | -56.8% | 35.1Kas of Jul 2025 | 47.1K | — | 65.5K |
| Morrissey Michael JamesEVP, Head of Tech. Operations · 17 transactions | -44.5% | 34.1K | 34.0K | — | 58.3K |
| Denton Sheila A.EVP & General Counsel · 35 transactions | — | 26.6K | 60.1K | — | 28.2K |
| Upadhyay SuketuEVP & Chief Financial Officer · 1 transaction | — | 26.3K | 26.3K | — | — |
| Clancy Paul JDirector · 16 transactions | +74% | 25.4K | 25.8K | — | 15.0K |
| Bienaime Jean JacquesDirector · 5 transactions | +57.6% | 24.4K | 22.0K | — | — |
| Tray ThomasPrincipal Accounting Officer · 26 transactions | -3.1% | 23.8K | 15.0K | — | 15.1K |
| Harrigan EdmundDirector · 14 transactions | +91.5% | 22.8K | 10.9K | — | — |
| Fouse Jacqualyn ADirector · 3 transactions | +50% | 21.0K | 7.0K | — | — |
| High Katherine ADirector · 3 transactions | +87.5% | 15.0K | 7.0K | — | — |
| Trotta MatteoEVP, GM, Dermatology US · 6 transactions | — | 14.9K | 15.7K | — | — |
| Brawley Otis WDirector · 3 transactions | +118.4% | 12.9K | 7.0K | — | — |
| Basi Ramitpal KEVP, Human Resources · 2 transactions | — | 11.0K | 6.5K | — | — |
| Hoffman Richard A.EVP & General Counsel · 1 transaction | — | 9.5K | 9.5K | — | — |
| Gardner David HEVP, Chief Strategy Officer · 1 transaction | — | 9.4K | 9.4K | — | — |
| Schaffert SusanneDirector · 4 transactions | +17.9% | 4.9Kas of Jun 2025 | 5.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -588.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.